KCNJ2: Inward rectifier potassium channel 2
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who Is On It, and How Far Along
Every drug ChEMBL records acting on KCNJ2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Drug | Furthest stage | Sponsor | Modality | Action | Mechanism | Open trials | Warnings |
|---|---|---|---|---|---|---|---|
| Dronedarone | Approved | Sanofi | Small molecule | Blocker | Inward rectifier potassium channel 2 blocker | 8 | Boxed warning |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Andersen-Tawil syndrome
- 0.84
- Short QT syndrome type 3
- 0.71
- Short QT syndrome
- 0.70
- Atrial fibrillation, familial, 9
- 0.69
- Abnormality of the cardiovascular system
- 0.54
- Cardiac arrhythmia
- 0.52
- Periodic paralysis
- 0.51
- Atrial flutter
- 0.39
- Familial atrial fibrillation
- 0.37
- Angina pectoris
- 0.37
- Thyrotoxic periodic paralysis
- 0.36
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1914276, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P63252, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets